NCT07100600View on ClinicalTrials.gov

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

PHASE2RecruitingINTERVENTIONAL

Enrollment

224

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

July 30, 2030

Study Completion Date

December 30, 2032

Conditions

HER2-positive Advanced Breast CancerBrain MetastasesRadiotherapy

Interventions

DRUG

Trastuzumab Rezetecan

Trastuzumab Rezetecan：4.8mg/kg Q3W

RADIATION

FSRT or WBRT

FSRT （8Gy/3-5 fx）or WBRT（30Gy/10fx）

Trial Locations (1)

Unknown

RECRUITING

Professor, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV

NCT07100600 - Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases | Biotech Hunter | Biotech Hunter